PALIPERIDONE PALMITATE
| Brand name | ERZOFRI |
|---|---|
| Active ingredient | PALIPERIDONE PALMITATE |
| Strength | 351MG/2.25ML (156MG/ML) |
| Dosage form | SUSPENSION, EXTENDED RELEASE |
| Route | INTRAMUSCULAR |
| Modality | Small molecule |
| FDA approval | July 2024 |
| Marketing status | RX |
| Patent | Expires | Type |
|---|---|---|
| 11666573 | September 2039 | use U-3968 |
| 12128049 | October 2038 | use U-3968 |
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.